LWBC research funding opportunities
Updated December 2019. Please check regularly for new information.
Cancer Research UK
Children and Young People’s Cancer Innovation Award
Amount: Up to £1m
Period: Up to 3 years
Deadline: 10 January 2020
Research area: New paediatric research funding call as part of Cancer Research UK’s new strategy to prioritise research for children and young people’s cancer. Proposals encouraged include:
- Development of more effective and/or less toxic treatments to improve long-term health and quality of life
Population Research Committee (PRC) Programme Awards
Amount: No set value (contact Funding Manager)
Period: Up to 5 years
Preliminary submission: 5 March 2020
Final submission: 18 June 2020
- Cancer aetiology
- Early diagnosis
- Behavioural research
- Cancer prevention
- Statistics and methodology
NOTE: You must contact the funding manager for this scheme to discuss your proposal before starting your application.
PRC remit relevant to LBWC research priorities:
- Epidemiological studies looking at long-term side-effects, late-effects of cancer/cancer treatment if also looking at differences in overall mortality/survival (priorities 5, 6, 10).
- Epidemiological studies looking at the effect of co-morbidities on cancer survival (priority 3).
- Behavioural interventions to improve cancer survival, reduce cancer progression or reduce cancer recurrence (priorities 9, 11, 15).
- Investigation of perceptions of cancer by minority ethnic groups, if perceptions shown to affect health-seeking behaviours (e.g. attendance at screening, vaccination uptake) and the aim of the project is to improve health-seeking behaviours (priority 23).
- Study of follow-up approaches to detect cancer recurrence e.g. to inform strategies for prevention of recurrence or early diagnosis of recurrence (priority 25).
To enquire about the PRC Programme Award and other PRC funding opportunities contact the Funding Manager at email@example.com.
Medical Research Council (MRC)
Tackling multimorbidity at scale: Understanding disease clusters, determinants & biological pathways
Amount: Consolidator grant up to £100k; Research Collaborative award up to £5m
Period: Consolidator grant for up to 6 months leading up to Research Collaborative award proposal (up to 4 years)
Deadline: 11 February 2020
Remit and scope:
- Identify and describe new disease clusters
- Multimorbidity at different stages of the life course
- Uncovering, validating and targeting shared determinants and mechanistic pathways
- Early detection/prediction
Relevant LWBC research priority: 3
GACD: Primary and Secondary Prevention of Cancer Funding Call
Amount: £6m total available to fund several awards
Period: Contact awarding body for information
Deadline: 30 April 2020
Scope: Proposals must focus on implementation research for the primary and/or secondary prevention of cancer in Lower and Middle Income Countries (LMIC). The Principal Investigators applying for this call must be hosted by a UK institution which is eligible for MRC funding[AH-UM6].
Relevant LWBC research priority: 11
National Institute for Health Research (NIHR)
Efficacy and Mechanisms Evaluation (EME) Programme: 19/139 Mitigation of the adverse effects of health and social care interventions
Amount: No fixed limit
Period: No fixed limit
Deadline: 1pm 16 April 2020
Applications are sought for research to evaluate interventions for the avoidance, management or amelioration of adverse effects experienced in the implementation of established health and social care interventions. Adverse effects associated with all types of intervention within the NHS and social care services, including adverse drug reactions, adverse surgical events and adverse effects of medical testing procedures are included within the remit of this call.
Areas of interest include, but are not limited to:
- Novel interventions to reduce adverse effects (e.g. to stop misprescribing)
- Novel interventions to identify patients at increased risk of adverse effects
- Studies to stratify patients to an established treatment that has very severe adverse effects
- Development of health technologies which promise an improved safety profile.
- Additive interventions which may improve the safety profile of existing technologies
- Pharmacogenomic strategies to mitigate the risks of exaggerated or diminished drug responses.
Applicants are encouraged to consider opportunities to embed the testing of mechanistic hypotheses within the main study. Also of interest are standalone studies of the mechanisms underpinning adverse effects associated with interventions (investigational or control) used in existing CSO- and NIHR-funded trials.
NOTE: For the purpose of this call, an ‘adverse effect’ is considered to be any undesired harmful effect resulting from the delivery of an established, licenced healthcare intervention, including (but not limited to) pharmaceuticals, medical tests and surgical procedures.
Relevant LWBC research priorities: several including 3, 6, 7, 10.
Themed calls and ongoing research priorities
NIHR themed calls are funding opportunities focussing on particular research areas in which all NIHR funding programmes participate. Recent themed calls (and still ongoing NIHR research priorities) relevant to LWBC research priorities include the following.
Frailty (includes complex health and care needs in older people)
The NIHR welcomes all relevant applications, and particularly those addressing the key themes:
- Transitions in care, service delivery and models of care
- Medicines management/polypharmacy
- Promoting healthy ageing/preventing ill health
- Patient-centred decision making
Relevant LWBC research priorities: 1, 2, 3
‘As chronic pain is itself a major contributor to the burden of ill health and to long term conditions … NIHR is initiating a new focus for research into this important issue.’
Relevant LWBC research priority: 8
Participating NIHR programmes and dates:
- Research for Patient Benefit Competition 41 – Open now to 1pm 18 March 2020
- Programme Grants for Applied Research Competition 32 – Open 6 February to 1 April 2020
- Efficacy and Mechanisms Evaluation (EME) Programme – see also EME 19/139 call above
- 19/103 Health Services and Delivery Research Programme (standard researcher-led) – Open now to 9 January 2020
- 19/104 Health Services and Delivery Research Programme (evidence synthesis) – Open now to 9 January
- Health Technology Assessment (HTA)
- Invention for Innovation (i4i)
- Public Health Research (PHR)
Research and Innovation for Global Health Transformation (RIGHT) – Call 3
NIHR funding call dedicated to management of multimorbidity in low and middle income countries. NIHR is seeking applications for NIHR RIGHT Call 3 that address applied health research in the following areas:
- Development and evaluation of interventions and strategies for improved management of multimorbidity.
- Healthcare systems strengthening in ODA-eligible countries: research into health care system improvements for improved treatments, management and care for those affected by multimorbidity in LMICs, including capacity building in the primary care setting.
Amount: Up to £5m
Period: Up to 4 years
Deadline: 1pm 15 January 2020 GMT (UK time). All applicants for RIGHT Call 3 were required to submit a mandatory ‘Intent to Submit’ form online by 29 November 2019 at 14:00 GMT (UK time) to be considered for this call. After submitting an Intent to Submit form, applicants should not wait for a response from the NIHR secretariat and should continue to submit their Stage 1 application along with their application for a Proposal and Partnership Development Award (PPDA).
NOTE: Awards are available for partnerships led by two Joint Lead Investigators (one from an LMIC and one from a UK institution).
Relevant LWBC research priority: 3
Contact firstname.lastname@example.org for further LWBC research funding queries.